Details for Patent: 7,820,671
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 7,820,671 protect, and when does it expire?
Patent 7,820,671 protects INCIVEK and is included in one NDA.
This patent has one hundred and five patent family members in thirty-six countries.
Summary for Patent: 7,820,671
| Title: | Peptidomimetic protease inhibitors |
| Abstract: | The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. |
| Inventor(s): | Babine; Robert Edward (Carlsbad, CA), Chen; Shu Hui (Thousand Oaks, CA), Collado; Ivan (Madrid, ES), Garcia-Paredes; Cristina (Madrid, ES), Glass; John Irvin (Germantown, MD), Guo; Deqi (Carmel, IN), Jin; Ling (Indianapolis, IN), Lamar; Jason Eric (Indianapolis, IN), Parker, III; Raymond Samuel (Doylestown, PA), Snyder; Nancy June (Lizton, IN), Sun; Xicheng David (Broumfied, CO), Tebbe; Mark Joseph (Zionsville, IN), Victor; Frantz (Indianapolis, IN), Wang; Q. May (Indianapolis, IN), Yip; Yvonne Yee Mai (Indianapolis, IN), Perni; Robert B. (Marlborough, MA), Farmer; Luc (Foxborough, MA) |
| Assignee: | Vertex Pharmaceuticals Incorporated (Cambridge, MA) |
| Application Number: | 10/344,112 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; |
Drugs Protected by US Patent 7,820,671
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms | INCIVEK | telaprevir | TABLET;ORAL | 201917-001 | May 23, 2011 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,820,671
| PCT Information | |||
| PCT Filed | August 31, 2001 | PCT Application Number: | PCT/US01/26008 |
| PCT Publication Date: | March 07, 2002 | PCT Publication Number: | WO02/18369 |
International Family Members for US Patent 7,820,671
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 030591 | See Plans and Pricing | |||
| Austria | 431358 | See Plans and Pricing | |||
| Austria | 483686 | See Plans and Pricing | |||
| Australia | 2001288318 | See Plans and Pricing | |||
| Australia | 8831801 | See Plans and Pricing | |||
| Brazil | 0113666 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
